Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LJPC

La Jolla Pharmaceutical (LJPC) Stock Price, News & Analysis

La Jolla Pharmaceutical logo

About La Jolla Pharmaceutical Stock (NASDAQ:LJPC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$3.12
$6.22
52-Week Range
N/A
Volume
66,708 shs
Average Volume
158,476 shs
Market Capitalization
$155.11 million
P/E Ratio
51.84
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive LJPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

LJPC Stock News Headlines

President Trump’s Project MAFA
President Trump’s Boldest Initiative Yet First came “Make America Great Again” (MAGA)… Then came “Make America Healthy Again” (MAHA)… Now comes President Trump’s boldest initiative yet. After a gathering in D.C. with some of the most powerful people in the world, Jeff Brown is now revealing the full details on “Project MAFA.” It’s a revolutionary plan to return America to an era of sound money, eliminate our looming debt disaster, kick off a Golden Century, and more – by July 25. Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%. Jeff Brown is sharing the details Wednesday, July 16, at 8 p.m. ET – including the name of a stock set to profit.
See More Headlines

LJPC Stock Analysis - Frequently Asked Questions

La Jolla Pharmaceutical (NASDAQ:LJPC) released its quarterly earnings data on Monday, May, 16th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.16. The biopharmaceutical company earned $10.43 million during the quarter, compared to analyst estimates of $13.10 million. La Jolla Pharmaceutical had a net margin of 8.54% and a negative trailing twelve-month return on equity of 5.46%.

Based on aggregate information from My MarketBeat watchlists, some other companies that La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), El Pollo Loco (LOCO), Intercept Pharmaceuticals (ICPT), Bristol Myers Squibb (BMY), Exelixis (EXEL), Sarepta Therapeutics (SRPT) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
5/16/2022
Today
7/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:LJPC
CIK
920465
Employees
61
Year Founded
N/A

Profitability

Trailing P/E Ratio
51.84
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$19.66 million
Pretax Margin
8.64%

Debt

Sales & Book Value

Annual Sales
$75.72 million
Price / Cash Flow
7.95
Book Value
($2.94) per share
Price / Book
N/A

Miscellaneous

Free Float
15,885,000
Market Cap
$155.11 million
Optionable
Optionable
Beta
2.39

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:LJPC) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners